#Global Bovine Respiratory Disease Treatment

[bishtmeenakshi]

The $64.2 billion Respiratory Market & Its Future Trends, Segmentation and Forecast

The global respiratory market size reached a staggering USD 42.3 billion in 2023. This impressive figure highlights the significant need for respiratory devices and treatments to address a wide range of respiratory conditions.  The market is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 7.4%, reaching an estimated USD 64.2 billion by 2030.  This growth can be attributed to several factors:

Rising Prevalence of Chronic Respiratory Diseases: Conditions like asthma, chronic obstructive pulmonary disease (COPD), and sleep apnea are on the rise due to factors like air pollution, smoking, and an aging population.

Increased Life Expectancy: With an aging population, the demand for respiratory support devices for chronic conditions is expected to rise.

Technological Advancements: The development of innovative respiratory devices, such as portable nebulizers and advanced ventilators, offers improved treatment options.

Growing Focus on Homecare: The increasing emphasis on home-based care for respiratory patients fuels the demand for user-friendly respiratory devices.

Respiratory Market Segmentation: Catering to Diverse Needs

The respiratory market segmentation reflects the vast array of products and technologies available to address different respiratory needs:

By Application:

Therapeutic Respiratory Devices Market: This segment includes devices used for treatment, such as nebulizers, metered-dose inhalers (MDIs), and continuous positive airway pressure (CPAP) machines used for sleep apnea. The respiratory inhalers market is a significant sub-segment due to the widespread use of inhalers for asthma and COPD.

Anesthesia & Respiratory Devices: Specialized equipment used in surgical settings to deliver oxygen and maintain proper ventilation during anesthesia. The anesthesia and respiratory devices market caters to the specific needs of hospitals and surgical centers.

Respiratory Gas Analysis: This technology analyzes the composition of respiratory gases to assess lung function and identify potential respiratory issues.

By Device Type:

Respiratory Care Devices: This broad category encompasses various devices used for diagnosis, treatment, and monitoring of respiratory conditions. Examples include nebulizers, inhalers, ventilators, and CPAP (continuous positive airway pressure) machines.

Respiratory Monitoring Devices: These devices track vital signs such as blood oxygen levels and respiratory rate, allowing for continuous monitoring of patients with respiratory difficulties. The respiratory monitoring devices market is experiencing significant growth due to the increasing focus on patient safety and remote monitoring.

Respiratory Measurement Devices: These devices measure lung function and capacity, providing vital diagnostic information for respiratory conditions. The respiratory disease testing market relies heavily on these devices for accurate diagnosis.

Respiratory Protective Equipment (RPE): This equipment protects users from inhaling harmful substances, including masks and respirators. The respiratory protective equipment market is expected to witness growth due to rising concerns about air pollution and pandemics.

Take a look at: Forecasting the Respiratory Market, Size, Segmentation and Future Trends

Top Players in Respiratory Market: Breathing Innovation

Several established medical device manufacturers and specialty respiratory companies dominate the respiratory market:

Some of the top players in the respiratory market include:

Philips Healthcare

ResMed

Medtronic

GE Healthcare

Fisher & Paykel

Emerging Markets: A Rising Demand for Respiratory Solutions

Developing nations with growing populations and increasing healthcare expenditure present a significant opportunity.  For instance, the bovine respiratory disease treatment market highlights the growing demand for respiratory solutions in the animal health sector.

Respiratory Market Trends: Shaping the Future of Respiratory Care

Exciting trends are shaping the respiratory market and transforming how we manage respiratory conditions:

Focus on Homecare Solutions: The emphasis on providing effective respiratory care solutions for patients in a home setting is driving innovation in portable and user-friendly devices.

Telemedicine Integration: Telehealth platforms allow remote monitoring and consultations with healthcare professionals, improving respiratory care management.

Connected Devices and Data Analytics: The integration of Internet of Things (IoT) technology allows for real-time data collection and analysis of respiratory parameters, leading to personalized treatment plans.

Emphasis on Early Detection and Prevention: The trend towards early detection and prevention of respiratory diseases through screening programs and lifestyle modifications is gaining momentum.

Challenges and Opportunities: Navigating the Respiratory Landscape

While the respiratory market offers promising opportunities, challenges also exist:

Challenges:

Cost Concerns: The high cost of some respiratory devices, particularly advanced equipment, can be a barrier to access for some patients.

Counterfeit Products: The presence of counterfeit respiratory products poses a safety risk and necessitates stringent quality control measures.

Compliance with Regulations: Navigating evolving regulatory requirements for medical devices can be complex and requires ongoing compliance efforts.

Opportunities:

Focus on Homecare: The trend towards homecare for respiratory patients creates a demand for portable and user-friendly respiratory devices.

Telemedicine Integration: Integrating respiratory monitoring devices with telemedicine platforms allows for remote patient monitoring and improved care coordination.

Emerging Technologies: The potential of new technologies like artificial intelligence and wearable devices can revolutionize respiratory care and diagnosis.

Respiratory Market Future Outlook: A Collaborative Approach

The respiratory market future outlook is promising, with a projected market size of  USD 64.2 billion by 2030. And this suggests a market driven by innovation, collaboration, and a focus on improving patient outcomes. Here's what we can expect:

Collaboration between Medical Device Manufacturers and Healthcare Providers: Collaboration between these entities will be crucial for developing and implementing effective respiratory care solutions that address real-world clinical needs.

Increased Focus on Patient Education and Self-Management: Empowering patients with respiratory conditions to manage their health through education and user-friendly technology will be a key focus.

Conclusion:  

The respiratory market plays a vital role in supporting lung health and improving the lives of millions suffering from respiratory illnesses.  As the market continues to evolve, driven by innovation, collaboration, and a focus on patient-centric care, we can expect a future where managing respiratory conditions becomes more effective, accessible, and empowering for individuals and healthcare professionals alike.You can also read about: Future Forecast and Trends in the $35.58 Billion Respiratory Market

[meghanester]

Albumin Market Size, Growth with a CAGR of ~6% During 2023-2035 and Attain ~USD 10 Billion by 2035

Research Nester’s recent market research analysis on “Albumin Market: Global Demand Analysis & Opportunity Outlook 2035” delivers a detailed competitors analysis and a detailed overview of the global albumin market in terms of market segmentation by type, grade, application, and by region.

Rise in the Number of Heart Operation Performed in the World to Promote Global Market Share of Albumin

The global albumin market is estimated to grow majorly on account of the increasing prevalence of diseases, that affects human organs and requires the surgery. For instance, Patients undergoing cardiac surgery may incur severe blood loss, demanding the replacement of electrolytes and blood-related materials. Therefore, rise in the number of cardiac surgeries will drive the demand for albumins. Every year, roughly 2 million individuals worldwide receive open-heart surgery in order to treat various cardiovascular conditions. On the other hand, it is expected that in the coming few years, over 50 million adults in the world will be suffering from chronic liver disease, since it occurrence rate has increase from 4.5% to 9.5% in the world wide population. Albumin is employed as a component in the removal of excess fluid from the abdomen in liver illnesses.

Get a Sample PDF Brochure: https://www.researchnester.com/sample-request-5035

Besides this, various development has taken place in albumin, which makes it suitable for treating or aiding the treatment of a wide range of diseases. For instance, some researchers have suggested in COVID-19 patients if albumin serum is injected at low levels. It helps identify patients who are at high risk of developing pneumonia or respiratory failure and patients who require longer stays at the hospital. Furthermore, the rising popularity of plant-based albumin has significant drive the industry’s expansion. Plant-based albumins enable adaptation and change in function. As a result, scientists are attempting to create novel plant-based albumins through genetic engineering or by optimizing natural sources.

Some of the major growth factors and challenges that are associated with the growth of the global albumin market are:

Growth Drivers:

Surge in the Cardiovascular Surgeries

Rising Use of Albumins in the Research and Development of Drug Delivery Systems

Challenges:

Many people have shown allergic reactions towards albumin and there are strict regulatory policies for approving the use of albumin are some of the major factors anticipated to hamper the global market size of albumin. Individuals with known allergies to albumin or other proteins are more prone to experience allergic responses. The symptoms range from, skin rashes to serious effects, like breathlessness, chest pain, and others. On the other hand, there are many substitutes present in the market which is also expected to impede market growth. Albumins face competition from various alternative products and technologies in different applications. Some of the tough competitors are synthetic polymers, hydroxyethyl starch (HES), recombinant proteins, human serum-derived proteins, nanoparticles, and liposomes.

Request for customization @ https://www.researchnester.com/customized-reports-5035

On the basis of application, the global albumin market is segmented into drug formulation & vaccines, therapeutics, research. The therapeutics segment is anticipated to bring in the most revenue by the end of 2035, with a considerable CAGR over the forecast period. The growth of the segment is credited to growing incidents involving severe burns and other injuries. Albumin is utilized as a plasma expander to restore and maintain intravascular volumes, which is lost due to severe burns. Furthermore, based on type, the market is further fragmented into recombinant albumin, human serum albumin, bovine albumin. Out of all, human serum albumin has shown tremendous growth and will be growing notably in the forecast period. The rising spending on the research and development of new drugs has boosted the demand for human serum albumin,

Furthermore, by the end of 2035, Europe is expected to control a significant share of the market.  Improved understanding of the role of albumin in various conditions and the development of innovative therapies have increased the utilization of albumin in Europe. The advancements in medical technology and practices have expanded the application of albumins in healthcare. On the other hand, the rising prevalence of liver diseases, such as cirrhosis, hepatitis, and liver failure are also anticipated to boost the market growth in the region.

Obtain this Report @ https://www.researchnester.com/reports/albumin-market/5035

This report also provides the existing competitive scenario of some of the key players of the global albumin market which includes company profiling of Octapharma AG, Bio Med International Pvt. Ltd., Baxter, Apotex Inc., Novozymes, Mitsubishi Tanabe Pharma America Inc., Merck KGaA, Akron Biotech, Thermo Fisher Scientific, and Grifols, S.A

About Us

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

[martynnx-blog]

Bovine Respiratory Disease Treatment Market 2018: Global Industry Analysis, Size, Share, Growth, Trends and Forecast To 2026

Bovine respiratory disease (BRD) is the most common disease, affecting the lower respiratory tract of cattle, causing bronchopneumonia and can lead to death. It is a multi-factorial syndrome that is mainly caused when a viral infection combines with a bacterial agent, and is further amplified by stress. BRD has numerous causes such as bacterial agents, including pasteurella multocida, haemophilus somnus, mannheimia haemolytica, and viral agents such as infectious bovine rhinotracheitis (IBR), bovine respiratory syncytial virus (BRSV), bovine viral diarrhea (BVD), and parainfluenza type-3 virus (PI-3).

Increasing cattle production due to rising demand for animal meat is expected to drive growth of bovine respiratory disease treatment market

According to a study published in the Turkish Journal of Veterinary and Animal Sciences in 2016, bovine respiratory disease (BRD) is the most common disease found in cattle, causing around 75% of morbidity and accounting for over 50% of cattle deaths. The increasing prevalence of BRD among cattle is expected to drive growth of the bovine respiratory disease treatment market in near future.

North America is expected to hold a dominant position in the bovine respiratory disease treatment market, owing to increasing prevalence of bovine respiratory disease

North America is expected to hold a dominant position in the bovine respiratory disease treatment market due to increasing prevalence of bovine respiratory disease in the region. According to Bovine Respiratory Disease Symposium, 2014, Bovine respiratory disease (BRD) is a worldwide health concern and is very common among cattle in North America. In feedlots, BRD accounts for 70-80% of all feedlot morbidity and 40-50% of all mortality, in the U.S. Asia Pacific is expected to show significant growth in bovine respiratory disease market due to increasing rearing of cattle in China. For instance, according to an article published by the U.S. Department of Agriculture in 2017, China is the world’s second-largest beef meat exporter.

Increasing development of innovative treatment measures for bovine respiratory disease to boost market growth

Key players in bovine respiratory disease treatment market include Zoetis Inc., Bayer AG, Merck & Co., Inc., Virbac Group, Boehringer Ingelheim GmbH, Elanco, Vetoquinol, and Bimeda Animal Health. In 2015, Bayer launched Immunostimulant Zelnate, which effectively reduces bovine respiratory disease (BRD) associated mortality and lung lesions in cattle. Zelnate is the first cytosine-phosphate-guanine (CpG) motif-based immunostimulant authorized by the U.S. Department of Agriculture.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1224

[ijcmcrjournal]

Scald Burn-COVID-19 Fallout by Vijay YB

Abstract

The COVID-19 pandemic has created a worldwide scenario of fear and anxiety. People are turning to unverified home remedies for prevention of the disease. Steam inhalation is used by the masses for prevention as well as treatment of COVID-19 without any proven data. Studies have shown steam inhalation to provide symptomatic relief in case of upper respiratory infection but has no significant effect on the viral load. Vessel containing hot water is commonly used for steam inhalation in developing countries, toppling off this vessel results in scald burn sometimes. During the period of lockdown, our hospital has treated an increase number of cases of scald burn due to steam inhalation. Our study focuses on evaluation of the scald burns occurring as complication of steam inhalation and its relation to increased fear of corona infection. 16 patients were treated during 6 months lockdown period from March-August 2020. Demographic data, mechanism of injury, treatment methods were evaluated. Patients with superficial second-degree burns were treated with regular dressing while those with deep second degree burns required collagen application. General awareness regarding the electrical steamers should be propagated to prevent scald burns cases associated with steam inhalation.

Keywords: Scald; COVID-19; Steam inhalation; Burns

Introduction

The Corona Virus Disease (COVID-19) pandemic has affected communities worldwide resulting in widespread emotion of trepidation among the masses of catching the disease. There are profound misconceptions regarding the preventive measures circulated by the social media and unverified home-made tutorial video, one such misconception is of steam inhalation. Any global disease outbreaks in past has shown people suffering from pandemic related anxiety that elevates levels of stress [1], corona virus related anxiety has been referred to as ‘coronaphobia’ by many [2]. Steam inhalation is a common home remedy for the upper respiratory tract infections. It has been recommended by many general practioners and popularised by media. A survey has shown that 80% of general practioners recommend steam inhalation as a home remedy for common cold [3]. However, there is no concrete proof that the steam inhalation helps in coronavirus infection. A Cochrane review for use of steam inhalation concluded that although there was evidence that symptoms were relieved, there was no objective improvement in the outcome measures like viral shedding or viral titres in nasal washing [4]. Vessel containing boiling water with or without added herbal concoction is most commonly used for steam inhalation, however many a times toppling of this vessels results in scald burns over the face, torso, perineum and lower limbs. Other safe methods are electrical steamer, respirator and rhinotherm. Paediatric and geriatric population are at a greater risk. With the increasing fear of COVID-19, increase in number of steam inhalation has resulted in increased number of scald burn cases. Our study focuses on evaluation of the scald burns occurring as complication of steam inhalation and its relation to increased fear of corona infection.

Material and Methods

A retrospective study of patients coming to our hospital was conducted from March 2020 to August 2020. Details of the 16 patients admitted or treated on the outpatient basis for scald injury due to steam inhalation was obtained from the database. Informed consent was obtained from the participants as per the guidelines of the ethical committee of our hospital. Data assessed includes: Demographics, mechanism of burns, total burn surface area % (TBSA %), modality of treatment, need for surgery, duration of hospital stay, outpatient follow-up. Patients with superficial second-degree burns were treated with regular dressing done on alternate days with paraffin gauze dressing and saline. Patient with deep second degree burns were treated with dry collagen sheet of bovine origin covered with non-adherent and absorbent dressing. All patients were given broad-spectrum antibiotic coverage.

Results

During the period of study, 16 patients with scald burns due to steam inhalation were treated at our centre, of which 7 were male 43.7% and 9 were female 56.2%. Out of 16 patients, 5 were less than 16 years old Table 1. Mean age was 25.5 years (range 2-52 years). The most common area involved in pediatric age group was abdomen while in adults lower limbs were most commonly involved. The monthly incidence of scald burns due to steam inhalation during the covid-19 lockdown period of 6 months is an average of 2.7/month. Of the 16 patients, mean TBSA was 4.5% (range 1-9 %). 10 patients had superficial second degree burns while 6 patients had mixed superficial and deep second degree burns. The duration of treatment ranged from 10-22 days, 6 patients were treated as in-patient while 105 patients took treatment on outpatient basis. No difference in the burn wound in terms of depth, extent or treatment was noticed depending on the mode of injury. 10 patients having superficial burns were treated with regular dressing with paraffin gauze and saline; while 6 patients having mixed second degree burns underwent collagen application Figure 1. Blister formation required sterile rupture of blister followed by application of non-adherent dressing. Complete epithelization was demonstrated in all patients. Figure 2 Out of 16 patients, 13 patients were using steam inhalation as a prophylaxis for COVID-19 infection while 3 patient was using it as a part of the treatment as suggested by their doctor. None of the patients had any permanent scarring or contracture formation, 4 patients had hypopigmentation while 2 patients had hyperpigmentation over the healed burn area.

Discussion

Burn injuries are complex and needs meticulous management. Amidst the lockdown, coronaphobia [2] has led to an increase in number of scald burns cases as a side effect. More and more people are turning to home remedies for preventive methods. Although steam inhalation is not proven to be a protective mechanism against COVID-19 infection, it has been used by the population and suggested by many doctors for symptomatic relief for common cold [5]. In a developing country like ours the most common method of steam inhalation comprises of a vessel containing boiling or hot water, the patient sits beside the vessel and breathes in the vapor with a cloth overhead to contain these vapors. Toppling off this vessel sometimes results in scald burns. There is a general misconception in population that heat destroys the corona virus, breathing in the vapors more deeply will be more beneficial 6 and due to this misbelief steam is used for inhalation, the temperature of which is around 100 degrees Celsius. Scald burns comprise the most common type of burns in pediatric age group [6]. 3 out of 9 patients 33.33% belonged to pediatric age group in this series. The most common mechanism of injury was falling of the vessel while removing the overhead cloth or while carrying the vessel. The most common area involved was abdomen in paediatric age group and lower limbs in adults. Other involved sites were chest anterior, upper limb and perineum. In a study conducted by Sarah et al [3] the most common area involved was abdomen followed by perineum. 5 patients with superficial second degree burns required regular dressings while; 4 patients with mixed second degree burns required collagen application. Figure 2 Superficial burns epithelise on its own with regular dressing. The dressing should be non-adherent to protect the delicate epithelium. Collagen acts as a scaffold for fibroblast and neutralizes collagenase, it delivers collagen-1 to the wound bed which becomes a template for new tissue growth [7]. The average healing period was of 14.5 days. Since medical treatment in government-funded institute is free of cost in our country, the cost of treatment could not be assessed. However, it can be said that the total cost of treatment of these burn wounds is substantial as these injuries could be easily avoided. Our hospital treated an increased number of scald burns occurring due to steam inhalation this year compared to the same months in previous years, being a tropical country scald burns are rare during march-September. In England, half of the burn centers responding to a survey by Brewster et al [8] reported an increase in scald cases related to steam inhalation during COVID-19 pandemic. The traditional method of steam inhalation by leaning over a vessel is dangerous; however, the use of advanced equipment like mechanical steamer, rhinotherm can reduce the number of burns cases. Due to the COVID-19 lockdown people are turning to the traditional method of steam inhalation due their ignorance, fear and anxiety coupled with 7 unavailability of modern equipment [9] Many case reports and studies [9] have already tried to draw attention to the hazards of steam inhalation however this practice still persist.

For more information about Article : https://ijclinmedcasereports.com/

https://ijclinmedcasereports.com/ijcmcr-rw-id-00117/ https://ijclinmedcasereports.com/pdf/IJCMCR-RW-00117.pdf

[ramshariraut]

"Latest Update 2021:Bovine Respiratory Disease Treatment  Market by COVID 19 Impact Analysis And Top Manufacturers: Merck, Boehringer Ingelheim, Bayer HealthCare, Zoetis, Elanco, Eli Lilly, Novartis Animal Health, Ceva, Bimeda, Plumbline Life Sciences, Huvepharma, Inovio Pharmaceuticals, Med-Pharmex, Norbrook Laboratories, Merial, Vibrac, Vetoquinol, "

Global Bovine Respiratory Disease Treatment  Market, Geography (North America (United States, Canada and Mexico), South America (China, Japan, Korea, India and Southeast Asia), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), Middle East and Africa (Saudi Arabia, Egypt, Nigeria and South Africa)) Industry Trends 2021-2028

<strong>Market Overview</strong> Illustrative analysis of critical sides such as resulting factors and competitive landscape are conveyed with the help of significant resources, such as charts, tables, graphs. The report executes a deep investigation of drivers and restraints operating in the market. The report also evaluates the trends observed in the parent market, along with the macro-economic indicators, prevailing factors, and market appeal according to different segments. The report also estimates the effect of different industrial sides on the Bovine Respiratory Disease Treatment   market divisions and regions. The research also divides the Bovine Respiratory Disease Treatment   Market on the basis of end-user, product type, application, and demography for the forecast period 2021–2028.

<strong> Request a sample Report of Bovine Respiratory Disease Treatment  Market @ <a href=https://www.statistifymarketresearch.com/reports/bovine-respiratory-disease-treatment-market/sample-request-88111>https://www.statistifymarketresearch.com/reports/bovine-respiratory-disease-treatment-market/sample-request-88111</a></strong>

<strong>Methodology</strong> The conditions influencing the market dynamics are considered and studied and examined to prepare an accurate report. In the report preparation process mainly two types of approaches are made- primary research approach and secondary research approach. In the primary research approach, both the supply and demand chain are interviewed where the supply chain consists of product, opinion leaders, etc. while the demand chain consists of industry experts. The secondary research approach involves various secondary sources like press releases, government agencies, and other commercial aspects of the market.

<strong>Report Summary</strong> Preparing a business report on Bovine Respiratory Disease Treatment    is the most important of all information-based writing because most of the business decisions are related to the organization after the evaluation of the situation as per the report. They are responsible for the documentation of the progress of the business and also serve several important purposes. The ability to write reports, quickly, and accurately is one of the key requirements of managers at every level. The reports allow them to convey vital information to subordinates and superiors. . The report on Bovine Respiratory Disease Treatment   prepared by us serves as a medium for understanding important business elements at the industrial and managerial level. Our report-making services entail flexible payment modes and budget-friendly rates.

<strong>Market segmentation</strong> The study splits the industry into a variety of sub-segments and thus represents the whole market. In addition, an estimate of the sales figures for the entire industry and its sub-segments are given in this report. It determines the variables that rapidly influence the market, including manufacturing methods and methodologies, channels for growth, and the product model. The report also outlines some of the biggest development opportunities, the introduction of the new products, market prediction, and forecasting, numerous economic factors that are key in deciding the Bovine Respiratory Disease Treatment  market pattern, buying decisions, and market attractiveness. The report would help stakeholders such as producers and distributors in finding and capturing high-potential markets. The research also addresses various environmental and regulatory critical factors.

<strong>Growth Mapping</strong> contains reason behind this report is to give a growth map with respect to the activities taken by key participants of the Bovine Respiratory Disease Treatment   market like item delivery, joint ventures,  influencing the Bovine Respiratory Disease Treatment   market and undertaking in general and furthermore influencing the business, import, fare, income and CAGR values. The report conveys the overall current realities about market definition, orders, applications, and commitment for the Bovine Respiratory Disease Treatment   market that are basic lead the market. The report moreover combines the overall organization profiles of the top players referred and also reflecting the drivers and limitations of the market with the support of SWOT analysis.

<strong>Top Listed Companies in the Bovine Respiratory Disease Treatment  Market Include</strong>

Merck, Boehringer Ingelheim, Bayer HealthCare, Zoetis, Elanco, Eli Lilly, Novartis Animal Health, Ceva, Bimeda, Plumbline Life Sciences, Huvepharma, Inovio Pharmaceuticals, Med-Pharmex, Norbrook Laboratories, Merial, Vibrac, Vetoquinol,

<strong>Reasons to buy this report:</strong> Learn about the Covid-19 Impact on Bovine Respiratory Disease Treatment   market strategies that are being adopted by leading respective organizations. To understand the future outlook and prospects for the market. Besides the standard structure reports, we also provide custom research according to specific requirements. To gain insightful analyses of the research Industry and have a comprehensive understanding of the global Bovine Respiratory Disease Treatment   market and its commercial landscape. To understand the future outlook and prospects for the Bovine Respiratory Disease Treatment   market with Marketing & Price (Price and Margin, Factors of Price Change, Manufacturers Gross Margin Analysis).

<strong>Request for Customization @ <a href=https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=88111>https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=88111</a></strong>

<strong>Regional Analysis</strong> Different regions of the world such as North America, Latin America, the Asia-Pacific region, Europe, and India, China, and Australia have been analyzed on the basis of various parameters that would benefit the development of the market in the area. It contains the territorial as well as the wide level investigation of the market. It was observed that North America and Asia-pacific countries have shown impressive development opportunities in their region. Asia-Pacific nations due to such a large population in the area could be the prime region for developing a fully flourishing market full of consumer and low-cost labor. However, Europe, being a region of most developed countries seems to be lagging in the survey due to its climatic-driven guidelines which will affect the new settlement of the market.

<strong>Customization of the report: </strong> The customized report is provided by our consultancy at a reasonable price. We provide updated information according to the requirements of the customers in the market world.

<strong>Benefits:</strong> 1. Well updated information. 2. Statistical report provided. 3. Discount offer in customization. 4. Service at the global level. 5. Company research report provided.

<strong>Services:</strong> 1. Expert analysts at your service. 2. Service according to your needs 3. Clearance of your queries. 4. Whole day service 5. Well updated Report.

<strong>Frequently Asked Questions?</strong> Q1. What is the total market value of the Bovine Respiratory Disease Treatment  market report? Q2. What would be the forecast period in the Bovine Respiratory Disease Treatment  market report? Q3. What is the base year considered in the Bovine Respiratory Disease Treatment   market report? Q4. Which are the top companies hold the market share in the Bovine Respiratory Disease Treatment   market ? Q5. Which is expected to be the fastest growing segment in the Bovine Respiratory Disease Treatment   market? Q6. Which market holds the maximum market share of the Bovine Respiratory Disease Treatment   market ? Q7. How the company profile has been selected? Q8. What will be the market value of the Bovine Respiratory Disease Treatment  market in 2028?

<strong>Why do companies trust Statistify Market Research?</strong> Statistify Market Research rendering surveys, indemnity, data, facts, enumeration on worldwide as well as local variables is one of the notable market research and expert company based in India. It covers automobiles, medicine, and healthcare, food and beverage, semiconductor and electronics market, chemicals, ICT(Information and Communications Technology), packaging, consumer goods. The flourishing company has a certain specified quality which provides customer satisfaction with excellent commitment and is highly time-oriented thus bringing positive results for our customers.

<strong>Company Name - Statistify Market Research</strong> Office Address - 156, Sector 9 Vasundhra Aptts Rohini, New Delhi 110085 IN Telephone Numbers - (+44) 162-237-1047 (+44) 162-237-1047 Email ID - <a href="mailto:sales@statistifymarketresearch.com"><strong>sales@statistifymarketresearch.com</strong></a> Contact Us – <a href="https://www.statistifymarketresearch.com/contact-us/"><strong>https://www.statistifymarketresearch.com/contact-us/</strong></a>

[decisionforsight]

Global Bovine Respiratory Disease Treatment Market

Global Bovine Respiratory Disease Treatment Market Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2030

Bovine respiratory disease (BRD) is the most common and costly disease attacking beef cattle in the world. It is a complex, bacterial infection that causes pneumonia in calves which can be fatal. Symptoms including such as high fever, nasal discharge, rapid and shallow breathing, coughing, diminished, or no appetite. It is not a contagious disease. For the treatment of the BRD, vaccines are available. The most commonly used vaccine for veterinary respiratory diseases is antimicrobial agents, Non-steroidal anti-inflammatory drugs (NSAIDs), mucolytic agents. Oral rehydration, fluids, Bronchodilators, and immunomodulators. The global bovine respiratory disease treatment market size valued USD 449 million in 2020 is expected to reach USD 3279.78 million growing with a CAGR of 22 % over the forecast period.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.decisionforesight.com/request-sample/DFS020209

Market Dynamics and Factors:

According to the study, the increasing consumption of beef and the rising population are the major factors that are driving the bovine respiratory disease treatment market. The increase in beef consumption is due to the rising population and increasing disposable income, across the globe. Bovine Respiratory Disease (BRD) has a negative impact on the dairy and beef industries, due to calf mortality, treatment expenses, and additional labor costs. Additionally, BRD adversely affects the reproductive performance, growth, and lifespan of cattle. Consequently, there is a huge necessity for bovine respiratory disease treatment market. Moreover, to meet, the increasing demand for beef, most of the countries in the world are expanding the production of cattle meat. The rising demand for beef, increased production, leads to the growing importance of bovine respiratory disease treatment market. There are certain difficulties that are associated with the diagnosis of the BRD. Animals suffering from BRD often show signs of depression, weight loss, cough, nasal discharge, high fever, increased respiratory rate, and abnormal pulmonary sound on auscultation. The presumptive diagnosis after a physical examination is difficult, owing to the similarities of clinical signs and variation of possible bacteria. Hence, the complex diagnostic procedure is controlled the bovine respiratory disease treatment market growth.

Market Segmentation:

Global Bovine Respiratory Disease Treatment Market – By Drug Type

Antibiotics

Vaccines

NSAIDs

Immunomodulators

Others

Global Bovine Respiratory Disease Treatment Market – By Disease Type 

Upper Respiratory Tract Infections

Pneumonia

Diphtheria

Global Bovine Respiratory Disease Treatment Market – By Distribution Channel 

Veterinary Hospitals

Veterinary Clinics

Private Veterinary Pharmacies

Veterinary Research Institutes

Online Pharmacies

Global Bovine Respiratory Disease Treatment Market – By Geography

North America

U.S.

Canada

Mexico

Europe

U.K.

France

Germany

Italy

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

Rest of Asia Pacific

ROW

Latin America

Middle East

Africa

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @ https://www.decisionforesight.com/toc-request/DFS020209 

Geographic Analysis:

Among the regions, North America is dominated the market in 2019 by contributing the largest bovine respiratory disease treatment market share in terms of revenue, due to increasing awareness about diseases and its treatment, high consumption of beef, increasing production and export beef, and the presence of companies available for manufacturing vaccines for bovine respiratory diseases. Asia Pacific is anticipated to grow at a higher CAGR Around 8.2% during the forecast period. Because of the growing population in India and China.

Competitive Scenario:

The market key players operating in the bovine respiratory disease treatment industry are Bayer Corporation, Boehringer Ingelheim GmbH, Bimeda Animal Health, Elanco, Vetoquinol S.A., Merck & Co Inc., Zoetis Inc., Novartis Animal Health, Vibrac S.A., Ceva Sante Animale, and Bimeda Animal Health.

Connect to Analyst @ https://www.decisionforesight.com/speak-analyst/DFS020209 

How will this Market Intelligence Report Benefit You?

The report offers statistical data in terms of value (US$) as well as Volume (units) till 2030.

Exclusive insight into the key trends affecting the Global Bovine Respiratory Disease Treatment industry, although key threats, opportunities and disruptive technologies that could shape the Global Bovine Respiratory Disease Treatment Market supply and demand.

The report tracks the leading market players that will shape and impact the Global Bovine Respiratory Disease Treatment Market most.

The data analysis present in the Global Bovine Respiratory Disease Treatment Market report is based on the combination of both primary and secondary resources.

The report helps you to understand the real effects of key market drivers or retainers on Global Bovine Respiratory Disease Treatment Market business.

The 2021 Annual Global Bovine Respiratory Disease Treatment Market offers:

100+ charts exploring and analysing the Global Bovine Respiratory Disease Treatment Market from critical angles including retail forecasts, consumer demand, production and more

15+ profiles of top producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Benchmark wholesale prices, market position, plus prices for raw materials involved in Global Bovine Respiratory Disease Treatment Market type

Buy This Premium Research Report@ https://www.decisionforesight.com/checkout/DFS020209 

About Us:

Decision Foresight is a market research organization known for its reliable and genuine content, market estimation and the best analysis which is designed to deliver state-of-the-art quality syndicate reports to our customers. Apart from syndicate reports, you will find the best market insights, strategies that will help in taking better business decisions on subjects that may require you to develop and grow your business-like health, science, technology and many more. At Decision Foresight, we truly believe in disseminating the right piece of knowledge to a large section of the audience and cover the in-depth insights of market leaders across various verticals and horizontals.

Contact:

Email: sales@decisionforesight.com

For Latest Update Follow Us:

https://www.facebook.com/Decision-Foresight-110793387201935

https://twitter.com/DecisionFs

https://www.linkedin.com/company/decision-foresight/

[prince94karan]

The report presents a professional and deep analysis of the present state of Bovine Respiratory Disease Treatment Market that includes major players like manufacturers, suppliers, distributors, traders, customers, investors and etc. The report also helps in understanding Bovine Respiratory Disease Treatment Market dynamic structure by identifying and analyzing the market segments and project the market size.

[healthcare-market]

Bovine Respiratory Disease Treatment Market to Witness Widespread Expansion by 2024

The demand within the global market for bovine respiratory disease treatment has been rising on account of advancements in the field of pulmonary disease treatment, finds TMR. The vendors operating in the global market for bovine respiratory disease treatment have been making ardent efforts to ensure a regular inflow of profits in their kitty. There is a dire need for smaller market vendors to form alliances among themselves in order to sustain the global market for bovine respiratory disease treatment. Furthermore, the leading market vendors are also projected to stay at the brink of innovation and strategising to continue their supremacy in the market.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13700

The past decade has witnessed key advancements as well as prominent changes in the way the healthcare sector functions. This factor needs to be considered while gauging the growth prospects of the market vendors in the global bovine respiratory disease treatment market. Furthermore, the presence of a seamless pharmaceutical industry has also aided the growth of the vendors in this market. It is projected that the vendors in the global bovine respiratory disease treatment market would bank on their ability to introduce new and more effective products. Some of the key vendors in the global market for bovine respiratory disease treatment market are Ceva, Merck & Co., Inc., and Boehringer Ingelheim GmbH.

Request for Analysis of COVID19 Impact on Bovine Respiratory Disease Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=13700

Transparency Market Research (TMR) predict that the global bovine respiratory disease treatment market would expand at a sturdy CAGR of 7.6% over the period between 2016 to 2024. Furthermore, the total worth of the global bovine respiratory disease treatment market stood at US$805.9 mn in 2015, and this value is expected to reach a value of US$1543.9 mn by 2024. On the basis of geography, the demand within the market for bovine respiratory disease treatment in Asia Pacific is expected to expand alongside the growing population in India and China.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=13700

Focus on Lung-Care to Propel Market Demand

The field of pulmonary treatments has gained traction across the globe in recent times. This factor is projected to bring in voluminous revenues into the global bovine respiratory disease treatment market in the years to come. Furthermore, patients suffering from bovine respiratory disease are at a risk of acquiring several other diseases and disorders. This factor has also played a crucial role in the growth of the global bovine respiratory disease treatment market. Moreover, the huge amounts of money spend on healthcare and disease treatment across the world has also given an impetus to the growth of the global bovine respiratory disease treatment market.

Buy now Bovine Respiratory Disease Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=13700&ltype=S

Sale of OCT Medications could Hamper Growth

Multiple treatments lines for bovine respiratory disease exist across the globe. Hence, there is little contention about the fact that the global market for bovine respiratory disease treatment would expand at a stellar pace. However, a number of over the counter medications can have adverse side effects for patients. This factor could restrain demand within the global market for bovine respiratory disease treatment in the years to come. Nevertheless, the changing lifestyles of the masses and increased focus given on pulmonary care shall continue to propel market demand.

The review is based on TMR’s report titled, “Bovine Respiratory Disease Treatment Market (Treatment Type - Vaccines, Antibiotics, NSAIDs, and Immunomodulators; Disease Type - Upper Respiratory Tract Infections, Pneumonia (Lower Respiratory Tract Infection), and Diphtheria; Distribution Channel - Veterinary Hospitals, Veterinary Clinics, Private Veterinary Pharmacies, and Veterinary Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024”.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/magnifying-prevalence-of-malnutrition-and-other-disorders-to-add-extra-stars-of-growth-global-medical-foods-market-to-reach-valuation-of-us-33-3-bn-by-2030--301123806.html

https://www.prnewswire.com/news-releases/technological-strides-in-ultrasound-devices-market-expand-scope-of-diagnosing-complex-diseases-market-to-clock-cagr-of-5-6-from-2018-to-2026-tmr-301129995.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com/

[himanshiposts]

The global Bovine Respiratory Disease Treatment market was valued USD 70 Million in 2019 and is projected to reach 186.3 Million by 2026, expanding at a CAGR of 18.3 % during the forecast period 2020 –2026.

[ezatluba]

Jason Gale

November 11, 2019

With African swine fever wiping out a quarter of the world’s pigs, primarily in China, doctors and drugmakers around the world are sounding the alarm about a possible prolonged shortage of heparin, a critically important blood thinner. The drug, derived from pig intestines, is widely used to treat heart attacks and prevent deadly blood clots. China has been the primary source of the medicine, and the crisis there highlights a need to develop alternate supplies.

1. What is heparin?

Heparin is a naturally derived, sugar-based molecule that’s administered by injection or infusion to prevent blood from coagulating and causing vessel-blocking clots that can starve organs of critical oxygen. Discovered more than a century ago, today some 10 million to 12 million people in the U.S. alone are treated with heparin each year, with the drug’s global sales exceeding 200 tons, or $5 billion, annually. A dose though is inexpensive, costing less than a packet of bandages.

2. Why is it important?

It’s routinely prescribed for heart attack patients with clogged arteries, patients undergoing major orthopedic and cardiac surgery, and patients with a central venous catheter or receiving a blood transfusion. Recipients of certain life-saving treatments such as blood-cleaning kidney dialysis or mechanical heart and lung support receive it, as do patients who are immobile for long periods. Heparin is often used to coat materials such as coronary stents that are in contact with blood. It’s the preferred anticoagulant for hospitalized patients because it works rapidly, can be carefully administered and there’s an effective antidote for it: protamine sulfate. A study by the Royal Children’s Hospital in Melbourne found as many as 15% of patients are exposed to heparin in some form on a daily basis.

3. What’s the concern?

Researchers are warning of an “imminent risk” of a global shortage because of the unprecedented scale of the cull. Most heparin-based drugs are sourced from the intestinal lining of slaughtered pigs. About 60% to 80% of the active key ingredient is prepared by companies in China and formulated into ready-to-use drugs by pharmaceutical companies around the world. China, home to half the planet’s pigs, is the only country that can meet the global demand for the raw material. The World Health Organization recommends governments stockpile heparin as an essential medicine.

Heparin shortage looms as the number of pigs slaughtered annually dwindles

4. What’s the supply like now?

A U.S. congressional committee asked the Food and Drug Administration in July to monitor heparin supplies, noting a six-to-nine-month lag time before a shortage could affect the U.S. market. The agency said in October that there had been no impact. That might be because the outbreak caused a pig-killing frenzy that initially yielded plenty of heparin. However, as the number of hogs slaughtered in China falls, so too will the volume of the raw material. Drugmakers including Germany’s Fresenius SE and South Africa’s Aspen Pharmacare Holdings Ltd. have mentioned shortages linked to rising prices. Fresenius’s Kabi unit told its U.S. customers in July that it put heparin on a protective allocation list due to a potential shortage. Massachusetts General Hospital warned in August of an impending global shortage; the chief of its emergency preparedness team said stock levels were so low at one point that the Boston center was two weeks away from having to cancel lifesaving cardiac surgery.

5. Are there other sources of heparin?

Yes. Heparin can be extracted from other farm animals and was historically prepared from cow lung and sheep intestines. The outbreak of mad cow disease in Europe in the 1990s made pigs a preferred source in many countries. The FDA has encouraged the development of bovine-sourced heparin as an alternate to pigs, though products from other sources may require rigorous testing to obtain regulatory approval, which could result in delays in their availability. Alternative blood-thinners aren’t typically as safe, effective or cheap.

6. Has this happened before?

Yes, though the current African swine fever outbreak is on a much bigger scale, heightening quality and supply concerns. The most recent shortages reported by the FDA involved Baxter International Inc. and Hospira Inc., now part of Pfizer Inc., and date to 2017, when Hurricane Maria disrupted manufacturing in Puerto Rico. In Australia, Pfizer advised authorities in November of a temporary shortage of two lines of heparin owing to manufacturing issues unrelated to the swine fever in China. A 2006-2007 outbreak in China of porcine reproductive and respiratory syndrome, or blue-ear disease, slashed heparin supplies and allegedly prompted some adulteration of the raw material in China. U.S. and European regulatory officials determined a cheaper substance derived from shark cartilage was added to mimic heparin’s anticoagulant properties. That tainted product made its way into the global supply chain, killing 149 people in 11 countries, including at least 81 in the U.S. Baxter recalled its heparin injection products in the U.S. in 2008 but faced more than 1,000 related lawsuits. China never formally accepted responsibility. In October 2018, the Italian Medicines Agency found serious manufacturing violations during an inspection of a heparin plant in Sichuan, China, and recommended the facility be banned from supplying the drug ingredient to the European Union.

[healthyworthyofficial]

In Coronavirus, China Weighs Benefits of Buffalo Horn and Other Remedies

As it races to treat patients infected with the new coronavirus, the Chinese government is seeing potential in a cocktail of antiviral drugs. It is also recommending the Peaceful Palace Bovine Pill, a traditional Chinese medicine made with the gallstone of cattle, buffalo horn, jasmine and pearl. There is no known cure for the coronavirus that has sickened more than 28,000 people and killed 563 in China. The country’s National Health Commission says doctors should try treating patients mainly with a combination of Western drugs used to treat HIV and fight viruses, depending on the severity of illness. But the government is also looking at ways to supplement the treatment with remedies that are integral to its national identity — traditional Chinese medicine. It has its supporters. “I think it is the correct approach,” said Cheng Yung-chi, a professor of pharmacology at Yale University School of Medicine. “The evidence is going to come and we have to give it the benefit of the doubt.” There is no clinical proof that the roots of various plants, licorice, and the Peaceful Palace Bovine Pill can help combat the deadly disease. Practitioners say the regimen could help ease symptoms such as swelling in the lungs, with fewer side effects. Critics say the use of such concoctions could raise concerns about patient safety.

The use of these ancient Chinese remedies dovetails with a push by Xi Jinping, China’s top leader, to harness them as a source of national pride. He has said that officials should place as much importance on traditional Chinese medicines as they do on Western medicines. His government has called for the remedies to be promoted in its “Belt and Road” trade route, China’s push to build ports, rail lines and other infrastructure around the world. In turning to traditional medicine, China is relying on past experience. During the severe acute respiratory syndrome, or SARS, outbreak in 2002 and 2003, doctors found that steroids prescribed to reduce inflammation had harmful side effects such as bone destruction. Chinese medicine, they said, would mitigate some of these adverse reactions. In its treatment plan for the coronavirus released on Wednesday, the National Health Commission recommended traditional Chinese medicine remedies that could be used with antiretroviral H.I.V. drugs like Lopinavir and Ritonavir. The national health department suggested trying the Peaceful Palace Bovine Pill for severe symptoms such as wheezing and respiratory distress. Some hospitals are already using a combination of Western and Chinese medicines. In recent weeks, Beijing’s health department reported that two patients who were discharged had been treated with traditional Chinese medicines together with other unspecified drugs. And in Guangzhou, a major city in the south, health officials said 50 patients reported having no more fever and half of them said their coughs went away after using traditional Chinese medicines and other drugs.

Shopkeepers dispensing Chinese medicines at a pharmacy in Hong Kong on Wednesday.Credit...Billy H.C. Kwok for The New York Times Doctors are conducting clinical trials to test the efficacy of traditional Chinese medicine in Wuhan, the epicenter of the coronavirus outbreak, said Dr. Cheng, the expert at Yale, who is also chairman of the Consortium for the Globalization of Chinese Medicine, a group of academics in the field. Jiang Xianfeng, a traditional Chinese medicine practitioner at United Family Health, a top hospital for the affluent in Beijing, said these medicines are safe, effective and easy to get. “Western medicine does not have better answers to this virus,” Mr. Jiang said. “The Chinese people have experienced these sort of plagues many times in our thousands of years of history. If traditional Chinese medicine was not effective, the Chinese people would already be destroyed.” After the SARS outbreak, the World Health Organization studied the use of traditional Chinese medicine during that period and determined that they were safe and showed some potential in relieving symptoms such as fatigue and shortness of breath. Researchers from the United States and Taiwan found that certain herbs could suppress the virus if prescribed at specific concentration levels, while other studies said their findings were inconclusive. That scientific uncertainty is not stopping the Chinese government. Since the second version of its treatment plan, the health commission has added more traditional Chinese medicines to the mix. The authorities in Wuhan say coronavirus patients with light or moderate symptoms should be treated with traditional Chinese medicine, the state-run Beijing News reported. Zhu Mao, a representative of a traditional Chinese medicine manufacturer in Hubei, said he was producing more than 20,000 prescriptions per day at the request of the government. On Jan. 25, the State Administration of Traditional Chinese medicine dispatched 25 teams of Chinese healers to Wuhan.

Chinese medicines for sale in Hong Kong.Credit...Billy H.C. Kwok for The New York Times Traditional Chinese medicine teaches that disease arises from imbalances in the body and that some people have “hot” constitutions, therefore making them vulnerable to fevers and inflammations. When someone gets a fever or a respiratory illness, it is not uncommon to have Chinese people say: “You are on fire.” Practitioners have determined that the coronavirus is a “hot” disease, and therefore, medicines should be prescribed to “clear the heat.” It is unclear how the science works behind these medicines. Compounding the problem: There is no standardization for these herbs and regulation is poor. Traditional Chinese medicine has also been linked to the consumption of exotic wild meats, though it is unclear whether the eating of the meats is really based on the practice. But some people, particularly in the south, believe that the way to achieving a balanced body is through eating certain meats. Wildlife markets such as the Huanan Seafood Market in Wuhan, the site that is believed to be the origin of the coronavirus, proliferated because of the demand for such meats. Laurie Garrett, a member of the World Economic Forum’s global health security advisory board who covered the SARS outbreak in China, said that using traditional Chinese medicine in the new coronavirus outbreak could be risky because the approach is not rigorously backed by research. “There’s no such thing as dosing,” she said. “It’s like being a chef in a kitchen.” The prestigious science journal Nature pointed out that dozens of women who had taken Chinese herbs as part of a weight-loss program ended up with kidney failure in the 1990s. Proponents of traditional Chinese medicine say the herbs were misused. Still, Nature argued in a 2017 editorial: “Hundreds of years of use in clinics that don’t standardize or analyze the clinical data are no match for blinded, controlled studies.”

A Chinese traditional medicine research laboratory in Lianyungang, Jiangsu Province, China, last year.Credit...Aleksandar Plavevski/EPA, via Shutterstock Doctors in neighboring Hong Kong, a semiautonomous region of China, are not convinced that traditional Chinese medicines can help. “I am not trying to devalue their treatment, but this is not something we practice,” said Arisina Ma, the president of the Hong Kong Public Doctors Association. In China, people have searched anxiously for ways to protect themselves. In many Chinese cities, some stood in line for hours to buy “Shuanghuanglian” — a herbal concoction that mixes flowers such as honeysuckle and forsythia, among other ingredients — after two government-backed research institutes published a study that said it was effective in preventing the coronavirus. Chen Xi, an assistant professor of health policy and economics at the Yale School of Public Health, urged the Chinese news media to be more careful in its reporting, saying that the potential for traditional Chinese medicine to inhibit a virus is not equivalent to a form of prevention or treatment. “If incidents like Shuanghuanglian happen again and again, it will lose the public trust, cause more panic, and go against the authorities’ advice to avoid crowd gathering,” Mr. Chen wrote. Qin Xi, a manager of a pharmacy in Beijing, said sales of some of his traditional Chinese medicines, including “Shuanghuanglian,” have been off the charts. “As for whether it works, who knows?” he said.

The Tongrentang traditional Chinese medicine pharmacy in Beijing.Credit...Andrea Verdelli for The New York TimesSource Link https://www.nytimes.com/2020/02/05/world/asia/coronavirus-traditional-chinese-medicine.html Read the full article

[kdmarketresearch]

Albumin Market Likely to Acquire Rapid Momentum as Technology Advances 2016-2023

KD Market research launches a new market research report on the Albumin Market. The study covers a detailed in-depth analysis of the global market along with the regional and country level analysis. The study also delivers a complete analysis about the major & niche players of Albumin Market which includes profiling of Grifols, S.A., Octapharma AG, China Biologic Products, Inc., Ventria Bioscience,. Shire Plc, CSL Limited, Albumedix Ltd., Merck KGaA , Thermo Fisher Scientific, Baxter International Inc.. Albumin is globular protein found in blood plasma. Serum albumin is the most abundant plasma protein, constituting around 50% of human plasma protein. Albumin is obtained from plasma fractionation process where human serum albumin and bovine serum albumin is most widely used. Recombinant albumin is produced using recombinant techniques in rice plants, yeast species, and other cell lines. Albumin is used as blood volumizer and is employed in the treatment of various diseases including surgical blood loss, shock, burns, trauma, chronic liver disease, hypovolemia, hemorrhage, acute liver failure, hypoalbuminemia, and acute respiratory distress syndrome.

Request sample Copy@ https://www.kdmarketresearch.com/sample/3208

The global albumin market was valued at $5,381 million in 2016, and is projected to reach $10,305 million at a CAGR of 9.6% from 2017 to 2023. Increase in prevalence of rare diseases, shocks, trauma, burns, and other fatalities is the major factor that contributes toward the growth of the albumin market. Moreover, other factors that fuel the market growth include increase in adoption of albumin products, growth in awareness about recombinant albumin products, and rise in non-therapeutic application of albumin as an excipient and drug formulating agent. However, stringent governmental regulations and risks of side effects associated with the use of albumin-based therapy impede the market growth. Conversely, development of cost-effective therapeutics through large scale production and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.

The global albumin market is segmented into product, application, and region. Based on product, the market is divided into human serum albumin, bovine serum albumin, and recombinant albumin. The applications covered in the study include therapeutics, drug formulation & vaccine, component of media, and other applications. Based on region, it is analyzed for North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

-The study provides an in-depth analysis of the global albumin market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.

-Comprehensive analysis of factors that drive and restrict the market growth is provided.

-Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.

-Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Key market segments:

By Product

-Human Serum Albumin -Bovine Serum Albumin -Recombinant Albumin

By Application

-Therapeutics -Drug Formulation & Vaccine -Component of Media -Other Applications

By Region

-North America -U.S. -Canada -Mexico -Europe -Germany -France -UK -Italy -Spain -Rest of Europe -Asia-Pacific -Japan -China -India -Australia -South Korea -Rest of Asia-Pacific -LAMEA -Brazil -Saudi Arabia -South Africa -Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

-Grifols, S.A. -Octapharma AG -China Biologic Products, Inc. -Ventria Bioscience -Shire Plc -CSL Limited -Albumedix Ltd. -Merck KGaA -Thermo Fisher Scientific -Baxter International Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

-Biotest AG -Medxbio Pte Ltd -Mitsubishi Tanabe Pharma Corporation -Kedrion Biopharma, Inc. -HiMedia Leading BioSciences Company -Celgene Corporation

Browse full Research Report with toc@ https://www.kdmarketresearch.com/report/3208/albumin-market-amr

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description 1.2. Key benefits for stakeholders 1.3. Key market segments 1.4. Research methodology

1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope 3.2. Key findings

3.2.1. Top investment pockets

3.3. Market share analysis, 2016 3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of rare diseases and various life-threatening conditions 3.4.1.2. Increase in demand for albumin 3.4.1.3. Growing preferences for recombinant albumin 3.4.1.4. Rise in non-therapeutic application of albumin

3.4.2. Restraints

3.4.2.1. Stringent government regulations 3.4.2.2. Risks associated with albumin

3.4.3. Opportunities

3.4.3.1. Opportunities in emerging economies 3.4.3.2. Development of cost effective therapeutics through large scale production

3.4.4. Impact analyses

3.5. Government regulations 3.6. Patent analysis (2013-2018)

3.6.1. Patent analysis, by year 3.6.2. Patent analysis for year 2017, by country

CHAPTER 4: ALBUMIN MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Human serum albumin

4.2.1. Key market trends, growth factors and opportunities 4.2.2. Market size and forecast, by region 4.2.3. Market analysis, by country

4.3. Bovine serum albumin

4.3.1. Key market trends, growth factors and opportunities 4.3.2. Market size and forecast, by region 4.3.3. Market analysis, by country

4.4. Recombinant albumin

4.4.1. Key market trends, growth factors and opportunities 4.4.2. Market size and forecast, by region 4.4.3. Market analysis, by country

CHAPTER 5: ALBUMIN MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast (value)

5.2. Therapeutics

5.2.1. Market size and forecast, by region 5.2.2. Market analysis, by country

5.3. Drug formulation & vaccines

5.3.1. Market size and forecast, by region 5.3.2. Market analysis, by country

5.4. Component of media

5.4.1. Market size and forecast, by region 5.4.2. Market analysis, by country

5.5. Other applications

5.5.1. Market size and forecast, by region 5.5.2. Market analysis, by country

CHAPTER 6: ALBUMIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors and opportunities 6.2.2. North America albumin market, by country

6.2.2.1. U.S.

6.2.2.1.1. Market size and forecast, by product 6.2.2.1.2. Market size and forecast, by application

6.2.2.2. Canada

6.2.2.2.1. Market size and forecast, by product 6.2.2.2.2. Market size and forecast, by application

6.2.2.3. Mexico

6.2.2.3.1. Market size and forecast, by product 6.2.2.3.2. Market size and forecast, by application

6.2.3. North America market size and forecast, by product 6.2.4. North America market size and forecast, by application

6.3. Europe

6.3.1. Key market trends, growth factors and opportunities 6.3.2. Europe market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Market size and forecast, by product 6.3.2.1.2. Market size and forecast, by application

6.3.2.2. France

6.3.2.2.1. Market size and forecast, by product 6.3.2.2.2. Market size and forecast, by application

6.3.2.3. UK

6.3.2.3.1. Market size and forecast, by product 6.3.2.3.2. Market size and forecast, by application

6.3.2.4. Italy

6.3.2.4.1. Market size and forecast, by product 6.3.2.4.2. Market size and forecast, by application

6.3.2.5. Spain

6.3.2.5.1. Market size and forecast, by product 6.3.2.5.2. Market size and forecast, by application

6.3.2.6. Rest of Europe

6.3.2.6.1. Market size and forecast, by product 6.3.2.6.2. Market size and forecast, by application 6.3.2.6.3. Europe market size and forecast, by product 6.3.2.6.4. Europe market size and forecast, by application

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors and opportunities 6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Market size and forecast, by product 6.4.2.1.2. Market size and forecast, by application

6.4.2.2. China

6.4.2.2.1. Market size and forecast, by product 6.4.2.2.2. Market size and forecast, by application

6.4.2.3. India

6.4.2.3.1. Market size and forecast, by product 6.4.2.3.2. Market size and forecast, by application

6.4.2.4. Australia

6.4.2.4.1. Market size and forecast, by product 6.4.2.4.2. Market size and forecast, by application

6.4.2.5. South Korea

6.4.2.5.1. Market size and forecast, by product 6.4.2.5.2. Market size and forecast, by application

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Market size and forecast, by product 6.4.2.6.2. Market size and forecast, by application

6.4.3. Asia-Pacific market size and forecast, by product 6.4.4. Asia-Pacific market size and forecast, by application

6.5. LAMEA

6.5.1. Key market trends, growth factors and opportunities 6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Market size and forecast, by product 6.5.2.1.2. Market size and forecast, by application

6.5.2.2. Saudi Arabia

6.5.2.2.1. Market size and forecast, by product 6.5.2.2.2. Market size and forecast, by application

6.5.2.3. South Africa

6.5.2.3.1. Market size and forecast, by type 6.5.2.3.2. Market size and forecast, by application

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Market size and forecast, by product 6.5.2.4.2. Market size and forecast, by application

6.5.3. LAMEA market size and forecast, by product 6.5.4. LAMEA market size and forecast, by application

CHAPTER 7: COMPANY PROFILES

7.1. Baxter International Inc.

7.1.1. Company overview 7.1.2. Company snapshot 7.1.3. Operating business segments 7.1.4. Product portfolio 7.1.5. Business performance

7.2. China Biologic Products Holdings, Inc.

7.2.1. Company overview 7.2.2. Company snapshot 7.2.3. Operating business segments 7.2.4. Product portfolio 7.2.5. Business performance

7.3. CSL Limited

7.3.1. Company overview 7.3.2. Company snapshot 7.3.3. Operating business segments 7.3.4. Product portfolio 7.3.5. Business performance

7.4. Grifols S.A. (Grifols International, S.A.)

7.4.1. Company overview 7.4.2. Company snapshot 7.4.3. Operating business segments 7.4.4. Product portfolio 7.4.5. Business performance 7.4.6. Key strategic moves and developments

7.5. Merck KGaA

7.5.1. Company overview 7.5.2. Company snapshot 7.5.3. Operating business segments 7.5.4. Product portfolio 7.5.5. Business performance 7.5.6. Key strategic moves and developments

7.6. Novozymes A/S (Albumedix Ltd.)

7.6.1. Company overview 7.6.2. Operating business segments 7.6.3. Product portfolio 7.6.4. Business performance

7.7. Octapharma AG

7.7.1. Company overview 7.7.2. Company snapshot 7.7.3. Operating business segments 7.7.4. Product portfolio 7.7.5. Business performance

7.8. Shire Plc. (Shire US, Inc.)

7.8.1. Company overview 7.8.2. Company snapshot 7.8.3. Operating business segments 7.8.4. Product portfolio 7.8.5. Business performance

7.9. Thermo Fisher Scientific Inc (Affymetrix, Inc.)

7.9.1. Company overview 7.9.2. Company snapshot 7.9.3. Operating business segments 7.9.4. Product portfolio 7.9.5. Business performance 7.9.6. Key strategic moves and developments

7.10. Ventria Bioscience

7.10.1. Company overview 7.10.2. Company snapshot 7.10.3. Operating product categories 7.10.4. Product portfolio

Request Exclusive Discount @ https://www.kdmarketresearch.com/discount/3208

About Us:

KD Market Research is one of the best market research organization that provides B2B research on the growth opportunities of the industry which is the prime factor of the overall revenue of the organization. We identify the pain points which our client is facing around revenue methods and provide them with a comprehensive database which helps them to make intelligent decisions that could ensure growth to the organization.

Our Services include market intelligence, competitive intelligence, and customized research. These research reports help the organizations to make quick and powerful decisions that make out highest growth in revenue.

Contact us -

KD Market Research

150 State Street, Albany,

New York, USA 12207

Website: www.kdmarketresearch.com

Email id-  sales@kdmarketresearch.com

More - https://kdmarketresearch.blogspot.com/

[ereportsmarket-blog]

Global Bovine Respiratory Disease Treatment Market 2018- Eli Lilly, Zoetis, Ceva, Huvepharma, Bimeda, Inovio Pharmaceuticals

Global Bovine Respiratory Disease Treatment Market 2018- Eli Lilly, Zoetis, Ceva, Huvepharma, Bimeda, Inovio Pharmaceuticals

eReportsMarket has recently added a new Bovine Respiratory Disease Treatment research report to its huge database of research studies. The research report, titled “Global Bovine Respiratory Disease Treatment Industry 2018 Market Research Report,” provides a comprehensive analysis of the industry, including an overview, Bovine Respiratory Disease Treatment market drivers and restraints, product…

[rohinic123-blog]

Smart Healthcare Products Market to Witness an Outstanding Growth by 2027

Transparency Market Research (TMR) has published a new report titled, ‘Smart Healthcare Products Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global smart healthcare products market was valued at US$ 37.5 Bn in 2018 and is projected to expand at a CAGR of 8.8% from 2019 to 2027.

Overview

Smart healthcare products enhance patient treatment and improve outcomes related to diagnostic tools along with improving their quality of life. These products come with embedded sensor technologies, communication, and data analytics techniques.

Smart healthcare products are usually used for physical monitoring of an individual for the diagnosis and ongoing disease treatment.

North America dominated the global smart healthcare products market in 2018 and the trend is anticipated to continue during the forecast period. Key factors attributing to its large share include favorable government initiatives, such as the implementation of the U.S. Health Information Technology for Economic and Clinical Health (HITECH) Act in 2009, which provided nearly US$ 64,000 to each healthcare practitioner who has adopted electronic health record systems.

Asia Pacific is likely to be a highly lucrative market for smart healthcare products and it is expected to expand at a high CAGR during the forecast period

Planning To Lay Down Future Strategy? Request Brochure Of Smart Healthcare Products Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9437

Smart healthcare products with IoT applications and Greater role of government in developing smart healthcare ecosystem to Drive Market

Advancements in sensors and the availability of IoT innovation are permitting medical equipment and healthcare hardware to gather, record and segment information that was not accessible in past.

Nowadays, smart healthcare gadgets are remote powered and can be utilized to monitor and gather patient data who are suffering from various medicinal syndromes.

Such critical data is also accessible to patients, and in addition medical groups can also gain access to it at any time and by using various platforms, such as smart phones or PCs.

Additionally, governments’ significant and developing part as payer, controller, and market-shaper in the worldwide smart healthcare division cannot be downplayed.

In many nations, governing authorities are major the funder and supplier of medicinal services for its population; this is an exceptionally costly obligation, as population is increasing.

Globally, various governments are implementing expansive changes by cutting expenses and enhancing the nature of their medical services frameworks.

These factors are expected to drive the smart healthcare products during the forecast period.

To Obtain All-Inclusive Information On Forecast Analysis Of Smart Healthcare Products Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=9437

Smart Pill Segment to Grow at a Faster Rate during the Forecast Period

Based on product type, the global smart healthcare products market has been divided into smart syringe, smart pills, RFID smart cabinets, and electronic health record.

The smart pill segment is expected to grow at a faster rate during the forecast period.

Increased patient preference for minimally invasive surgeries is considered as a major factor that would serve as a gateway for the growth of smart pills segment during the forecast period.

North America to Dominate Global Market

In terms of region, the global smart healthcare products market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global smart healthcare products market in 2018, followed by Europe.

North America accounted for major share of the global smart healthcare products market in 2018. Its dominance can be attributed to increase in prevalence and incidence of chronic diseases such as diabetes and cancer are becoming more common in Canada, and healthcare providers are investing more heavily in IT to account for the impending growth in demand for healthcare

The rise of the aging population is another reason to increase investments in healthcare IT, boosting the demand for smart healthcare products in North America

The smart healthcare products market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027.

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=9437

Competitive Landscape

The global smart healthcare products market is fragmented in terms of number of players. Key players in the global market include Epic System Corporation, Allscripts Healthcare Solutions, Inc., eClinicalWorks, CapsoVision, Medtronic, Olympus Corporation, Becton Dickinson and Company, Terumo Corporation, Stanley Healthcare, TAGSYS, among others.

More Trending Reports by Transparency Market Research –

Dental 3D Printing Market –

https://www.globenewswire.com/news-release/2019/03/28/1781467/0/en/Dental-3D-Printing-Market-will-be-worth-US-3-427-1-million-by-2025-TMR.html

Bovine Respiratory Disease Treatment Market –

https://www.biospace.com/article/bovine-respiratory-disease-treatment-market-pulmonary-care-and-preventive-measures-fuelling-advancement-in-treatment-procedures/

[mastcomm]

In Coronavirus, China Weighs Benefits of Buffalo Horn and Other Remedies

As it races to treat patients infected with the new coronavirus, the Chinese government is seeing potential in a cocktail of antiviral drugs. It is also recommending the Peaceful Palace Bovine Pill, a traditional Chinese medicine made with the gallstone of cattle, buffalo horn, jasmine and pearl.

There is no known cure for the coronavirus that has sickened 24,324 people and killed 490 in China. The country’s National Health Commission says doctors should try treating patients mainly with a combination of Western drugs used to treat HIV and fight viruses, depending on the severity of illness.

But the government is also looking at ways to supplement the treatment with remedies that are integral to its national identity — traditional Chinese medicine. It has its supporters.

“I think it is the correct approach,” said Cheng Yung-chi, a professor of pharmacology at Yale University School of Medicine. “The evidence is going to come and we have to give it the benefit of the doubt.”

There is no clinical proof that the roots of various plants, licorice, and the Peaceful Palace Bovine Pill can help combat the deadly disease. Practitioners say the regimen could help ease symptoms such as swelling in the lungs, with fewer side effects. Critics say the use of such concoctions could raise concerns about patient safety.

The use of these ancient Chinese remedies dovetails with a push by Xi Jinping, China’s top leader, to harness them as a source of national pride. He has said that officials should place as much importance on traditional Chinese medicines as they do on Western medicines. His government has called for the remedies to be promoted in its “Belt and Road” trade route, China’s push to build ports, rail lines and other infrastructure around the world.

In turning to traditional medicine, China is relying on past experience. During the severe acute respiratory syndrome, or SARS, outbreak in 2002 and 2003, doctors found that steroids prescribed to reduce inflammation had harmful side effects such as bone destruction. Chinese medicine, they said, would mitigate some of these adverse reactions.

In its treatment plan for the coronavirus released on Wednesday, the National Health Commission recommended traditional Chinese medicine remedies that could be used with antiretroviral H.I.V. drugs like Lopinavir and Ritonavir. The national health department suggested trying the Peaceful Palace Bovine Pill for severe symptoms such as wheezing and respiratory distress.

Some hospitals are already using a combination of Western and Chinese medicines. In recent weeks, Beijing’s health department reported that two patients who were discharged had been treated with traditional Chinese medicines together with other unspecified drugs. And in Guangzhou, a major city in the south, health officials said 50 patients reported having no more fever and half of them said their coughs went away after using traditional Chinese medicines and other drugs.

Doctors are conducting clinical trials to test the efficacy of traditional Chinese medicine in Wuhan, the epicenter of the coronavirus outbreak, said Dr. Cheng, the expert at Yale, who is also chairman of the Consortium for the Globalization of Chinese Medicine, a group of academics in the field.

Jiang Xianfeng, a traditional Chinese medicine practitioner at United Family Health, a top hospital for the affluent in Beijing, said these medicines are safe, effective and easy to get.

“Western medicine does not have better answers to this virus,” Mr. Jiang said. “The Chinese people have experienced these sort of plagues many times in our thousands of years of history. If traditional Chinese medicine was not effective, the Chinese people would already be destroyed.”

After the SARS outbreak, the World Health Organization studied the use of traditional Chinese medicine during that period and determined that they were safe and showed some potential in relieving symptoms such as fatigue and shortness of breath. Researchers from the United States and Taiwan found that certain herbs could suppress the virus if prescribed at specific concentration levels, while other studies said their findings were inconclusive.

That scientific uncertainty is not stopping the Chinese government. Since the second version of its treatment plan, the health commission has added more traditional Chinese medicines to the mix. The authorities in Wuhan say coronavirus patients with light or moderate symptoms should be treated with traditional Chinese medicine, the state-run Beijing News reported.

Zhu Mao, a representative of a traditional Chinese medicine manufacturer in Hubei, said he was producing more than 20,000 prescriptions per day at the request of the government. On Jan. 25, the State Administration of Traditional Chinese medicine dispatched 25 teams of Chinese healers to Wuhan.

Traditional Chinese medicine teaches that disease arises from imbalances in the body and that some people have “hot” constitutions, therefore making them vulnerable to fevers and inflammations. When someone gets a fever or a respiratory illness, it is not uncommon to have Chinese people say: “You are on fire.”

Practitioners have determined that the coronavirus is a “hot” disease, and therefore, medicines should be prescribed to “clear the heat.”

It is unclear how the science works behind these medicines. Compounding the problem: There is no standardization for these herbs and regulation is poor.

Traditional Chinese medicine has also been linked to the consumption of exotic wild meats, though it is unclear whether the eating of the meats is really based on the practice. But some people, particularly in the south, believe that the way to achieving a balanced body is through eating certain meats. Wildlife markets such as the Huanan Seafood Market in Wuhan, the site that is believed to be the origin of the coronavirus, proliferated because of the demand for such meats.

Laurie Garrett, a member of the World Economic Forum’s global health security advisory board who covered the SARS outbreak in China, said that using traditional Chinese medicine in the new coronavirus outbreak could be risky because the approach is not rigorously backed by research.

“There’s no such thing as dosing,” she said. “It’s like being a chef in a kitchen.”

The prestigious science journal Nature pointed out that dozens of women who had taken Chinese herbs as part of a weight-loss program ended up with kidney failure in the 1990s. Proponents of traditional Chinese medicine say the herbs were misused. Still, Nature argued in a 2017 editorial: “Hundreds of years of use in clinics that don’t standardize or analyze the clinical data are no match for blinded, controlled studies.”

Doctors in neighboring Hong Kong, a semiautonomous region of China, are not convinced that traditional Chinese medicines can help. “I am not trying to devalue their treatment, but this is not something we practice,” said Arisina Ma, the president of the Hong Kong Public Doctors Association.

In China, people have searched anxiously for ways to protect themselves. In many Chinese cities, some stood in line for hours to buy “Shuanghuanglian” — a herbal concoction that mixes flowers such as honeysuckle and forsythia, among other ingredients — after two government-backed research institutes published a study that said it was effective in preventing the coronavirus.

Chen Xi, an assistant professor of health policy and economics at the Yale School of Public Health, urged the Chinese news media to be more careful in its reporting, saying that the potential for traditional Chinese medicine to inhibit a virus is not equivalent to a form of prevention or treatment.

“If incidents like Shuanghuanglian happen again and again, it will lose the public trust, cause more panic, and go against the authorities’ advice to avoid crowd gathering,” Mr. Chen wrote.

Qin Xi, a manager of a pharmacy in Beijing, said sales of some of his traditional Chinese medicines, including “Shuanghuanglian,” have been off the charts. “As for whether it works, who knows?” he said.

Elsie Chen, Yiwei Wang and Zoe Mou contributed research from Beijing. Tiffany May contributed reporting from Hong Kong.

from WordPress https://mastcomm.com/in-coronavirus-china-weighs-benefits-of-buffalo-horn-and-other-remedies/

[decisionforsight]

Global Animal Therapeutics and Diagnostics Market

Global Animal Therapeutics and Diagnostics Market Size, Share, Growth, Industry Trends and Forecast 2020-2030

Animal Therapeutics and Diagnostics consolidates variety of instruments and treatment involving use of drugs for the animals. These diagnostic instruments help in the determination of causative agents of diseases. There is need to development in diagnostic instruments with continuous emergence of different diseases.  With rise in companion animals coupled with slight similarity of human & animal body in terms of structure & function has considered for safe and effective treatment for the animals. Animals are essential source of food, meat, milk, protein, and many other commercial products including leather. The increasing priority towards pet obesity, increase ownership of companion animals and increasing animal medical expenses is created the growth of the market. The most of countries are depends on animal husbandry for their income. Therefore, the demand for animal therapeutics and diagnostics projected to remain high in the forthcoming years. The global animal therapeutics and diagnostics market held USD 27572.7 million in 2020 and will register to grow at a CAGR of 6.9% during the forecast period.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.decisionforesight.com/request-sample/DFS020304

Market Dynamics and Factors:

Rapid increase in demand for animal-derived food products such as meat, the increase in pet ownership worldwide and are the primary drivers for the growth of the global animal therapeutics and diagnostics market. In addition, the increasing veterinary practitioners in developed regions and the rising expenditure on animal health and pet insurance are some of the other factors to fuel the growth of the market in the near future. For example, Bayer Animal Health launched Zelnate which is used for the treatment of bovine respiratory diseases in August 2015. Conversely, the lack of awareness regarding animal healthcare are responsible to restrain the market growth.  Additionally, rapid growth in reasearch and development in the veterinary therapeutics sector are also boosting the growth of market during the next coming years. On the contrary, the rising disposal income, prosperous livestock markets and exceptional animal products export abilities in developing region is creating immense opportunities for the market growth during forecast timeframe. However, on-going global efforts on diagnostic instrument investment and awareness about animal health care are considered to be the challenge for market in the near future.

Market Segmentation:

Global Animal Therapeutics and Diagnostics Market – By Therapeutic Products

Anti-Parasitic Drugs & Antibiotics

Anti-Inflammatory Drugs

Anaesthetics

Others

Global Animal Therapeutics and Diagnostics Market – By Diagnostics Products

Instruments

Consumables

Global Animal Therapeutics and Diagnostics Market – By Animal Type

Companion Animals

Cattle

Pigs

Poultry

Sheep

Global Animal Therapeutics and Diagnostics Market – By Geography

North America

U.S.

Canada

Mexico

Europe

U.K.

France

Germany

Italy

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

Rest of Asia Pacific

ROW

Latin America

Middle East

Africa

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @ https://www.decisionforesight.com/toc-request/DFS020304

Geographic Analysis:

North America is expected to largest share in the growth of the global animal therapeutics and diagnostics market, due to the strong economic development, the existence of better animal health care system, growing trend of pet rights, and higher stress on the impediment of diseases by owners and veterinarians in the region. Europe holds the major growth rate in the global market attributed to the changing food habits, and rising per capita expenditure on animal health. Furthermore, Asia pacific is anticipated to fastest growing regional market, owing to the growing trend of pet adoption, increasing livestock population, increase in the research on therapeutic drugs and diagnostic instruments and rapid urbanization during the forecast time frame. On the other hand, Latin America and the Middle East & Africa region are projected to continuous growth of the global market during the upcoming years.  Merck accounted 93% of Vallée S.A. in July 2016 for USD400 million to strengthen its presence in this region.

 Competitive Scenario:

The key players of global animal therapeutics and diagnostics markets are AUV Veterinary Cooperative, Bayer AG, Eli Lilly and Company, Boehringer, Ingelheim GmbH, Heska Corp., Merck & Co., Inc., Ceva Santé Animale, Sanofi S.A., Nutreco N.V., Virbac S.A., and Zoetis Inc.

Connect to Analyst @ https://www.decisionforesight.com/speak-analyst/DFS020304

How will this Market Intelligence Report Benefit You?

The report offers statistical data in terms of value (US$) as well as Volume (units) till 2030.

Exclusive insight into the key trends affecting the Global Animal Therapeutics and Diagnostics industry, although key threats, opportunities and disruptive technologies that could shape the Global Animal Therapeutics and Diagnostics Market supply and demand.

The report tracks the leading market players that will shape and impact the Global Animal Therapeutics and Diagnostics Market most.

The data analysis present in the Global Animal Therapeutics and Diagnostics Market report is based on the combination of both primary and secondary resources.

The report helps you to understand the real effects of key market drivers or retainers on Global Animal Therapeutics and Diagnostics Market business.

The 2021 Annual Global Animal Therapeutics and Diagnostics Market offers:

100+ charts exploring and analysing the Global Animal Therapeutics and Diagnostics Market from critical angles including retail forecasts, consumer demand, production and more

15+ profiles of top producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Benchmark wholesale prices, market position, plus prices for raw materials involved in Global Animal Therapeutics and Diagnostics Market type

Buy This Premium Research Report@ https://www.decisionforesight.com/checkout/DFS020304

About Us:

Decision Foresight is a market research organization known for its reliable and genuine content, market estimation and the best analysis which is designed to deliver state-of-the-art quality syndicate reports to our customers. Apart from syndicate reports, you will find the best market insights, strategies that will help in taking better business decisions on subjects that may require you to develop and grow your business-like health, science, technology and many more. At Decision Foresight, we truly believe in disseminating the right piece of knowledge to a large section of the audience and cover the in-depth insights of market leaders across various verticals and horizontals.

Contact:

Email: sales@decisionforesight.com

For Latest Update Follow Us:

https://www.facebook.com/Decision-Foresight-110793387201935

https://twitter.com/DecisionFs

https://www.linkedin.com/company/decision-foresight/